MCID: OPT006
MIFTS: 52

Optic Nerve Disease malady

Categories: Eye diseases, Neuronal diseases

Aliases & Classifications for Optic Nerve Disease

Aliases & Descriptions for Optic Nerve Disease:

Name: Optic Nerve Disease 12 14
Optic Neuropathy 12 29 52 69
Disorder of the Second Nerve 12
Disorder of the Optic Nerve 69
Optic Nerve Disorders 41
Optic Nerve Disorder 12

Classifications:



External Ids:

Disease Ontology 12 DOID:1891
MeSH 42 D009901
NCIt 47 C79698
ICD10 33 H47.0
UMLS 69 C0029132

Summaries for Optic Nerve Disease

MedlinePlus : 41 the optic nerve is a bundle of more than 1 million nerve fibers that carry visual messages. you have one connecting the back of each eye (your retina) to your brain. damage to an optic nerve can cause vision loss. the type of vision loss and how severe it is depends on where the damage occurs. it may affect one or both eyes. there are many different types of optic nerve disorders, including: glaucoma is a group of diseases that are the leading cause of blindness in the united states. glaucoma usually happens when the fluid pressure inside the eyes slowly rises and damages the optic nerve. optic neuritis is an inflammation of the optic nerve. causes include infections and immune-related illnesses such as multiple sclerosis. sometimes the cause is unknown. optic nerve atrophy is damage to the optic nerve. causes include poor blood flow to the eye, disease, trauma, or exposure to toxic substances. optic nerve head drusen are pockets of protein and calcium salts that build up in the optic nerve over time contact your health care provider if you are having vision problems. tests for optic nerve disorders may include eye exams, ophthalmoscopy (an examination of the back of your eye), and imaging tests. treatment depends on which disorder that you have. with some optic nerve disorders, you may get your vision back. with others, there is no treatment, or treatment may only prevent further vision loss.

MalaCards based summary : Optic Nerve Disease, also known as optic neuropathy, is related to nonarteritic anterior ischemic optic neuropathy and ischemic optic neuropathy, and has symptoms including eye manifestations and sciatica. An important gene associated with Optic Nerve Disease is MT-ND4 (Mitochondrially Encoded NADH:Ubiquinone Oxidoreductase Core Subunit 4), and among its related pathways/superpathways are Glucose / Energy Metabolism and GABAergic synapse. The drugs Dorzolamide and Timolol have been mentioned in the context of this disorder. Affiliated tissues include brain, retina and eye, and related phenotypes are growth/size/body region and muscle

Disease Ontology : 12 A cranial nerve disease that is located in the optic nerve.

Wikipedia : 71 The optic nerve, also known as cranial nerve II, is a paired nerve that transmits visual information... more...

Related Diseases for Optic Nerve Disease

Diseases related to Optic Nerve Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 63)
id Related Disease Score Top Affiliating Genes
1 nonarteritic anterior ischemic optic neuropathy 12.5
2 ischemic optic neuropathy 12.3
3 arteritic anterior ischemic optic neuropathy 12.2
4 leber hereditary optic neuropathy with dystonia 12.2
5 toxic optic neuropathy 12.0
6 nutritional optic neuropathy 12.0
7 autoimmune-related retinopathy and optic neuropathy 11.9
8 leber optic atrophy 11.8
9 mitochondrial complex i deficiency 11.1
10 antiphospholipid syndrome 11.1
11 optic atrophy 1 11.1
12 neuropathy 11.1
13 foster-kennedy syndrome 10.9
14 spastic paraplegia 3a, autosomal dominant 10.7
15 exfoliation syndrome 10.7
16 chiasmal syndrome 10.7
17 optic neuritis 10.7
18 ethylmalonic encephalopathy 10.7
19 autosomal dominant optic atrophy plus syndrome 10.7
20 acute inferoposterior infarction 10.3 MT-ND4 OPTN
21 pituitary hormone deficiency, combined, 4 10.3 MYOC OPTN
22 multiple cranial nerve palsy 10.3 MFRP OPTN
23 amyotrophic neuralgia 10.3 MFRP MT-ND4 OPTN
24 acute poststreptococcal glomerulonephritis 10.2 MFRP MYOC OPTN
25 chronic tympanitis 10.2 MYOC OPTN
26 brachymorphism-onychodysplasia-dysphalangism syndrome 10.2 OPA1 OPA3
27 opisthorchiasis 10.2 MYOC OPTN
28 ulcerative blepharitis 10.2 MT-ND4 NDUFA1
29 colorectal cancer 5 10.2 EDN1 MYOC OPTN
30 morbid obesity and spermatogenic failure 10.2 EDN1 MYOC OPA1 OPTN
31 lentigo maligna melanoma 10.2 MT-ND1 MT-ND4 MT-ND6
32 lactocele 10.2 EDN1 MYOC OPA1 OPTN
33 pulmonary hemosiderosis 10.2 AQP4 MOG MT-ND4
34 parkinson disease 6, early onset 10.2 MT-ND5 MT-ND6
35 status epilepticus 10.2 AQP4 MOG MT-ND4
36 schwannoma of twelfth cranial nerve 10.2 AQP4 BTD MOG
37 optic atrophy plus syndrome 10.1 MFN2 OPA1
38 mucinous intrahepatic cholangiocarcinoma 10.1 MT-ND4 MT-ND5 MT-ND6 NDUFA1
39 hypopigmentation of eyelid 10.1 MT-ND4 PDE5A
40 mental retardation with spastic paraplegia 10.1 MT-ND4 MT-ND5 MT-ND6
41 fibrosis of extraocular muscles, congenital, 3a 10.1 MFN1 MFN2 OPA1
42 uterine ligament serous adenocarcinoma 10.1 AQP4 MFN2 MFRP MT-ND4 MT-ND6
43 substance-induced psychosis 10.0 AQP4 MFRP MOG MT-ND4 OPTN
44 retinitis 10.0
45 enteropathica 10.0 MT-ND1 MT-ND4 MT-ND5 MT-ND6
46 retromolar area cancer 10.0 MT-ND1 MT-ND4 MT-ND5 MT-ND6
47 ndp-related retinopathies 10.0 MT-ND1 MT-ND4 MT-ND5 MT-ND6
48 myoclonic epilepsy associated with ragged-red fibers 10.0 MT-ND1 MT-ND4 MT-ND5 MT-ND6
49 mast cell neoplasm 10.0 MT-ND1 MT-ND4 MT-ND5 MT-ND6
50 autoimmune interstitial lung, joint, and kidney disease 9.9 MT-ND1 MT-ND4 MT-ND5 MT-ND6 NDUFA1

Graphical network of the top 20 diseases related to Optic Nerve Disease:



Diseases related to Optic Nerve Disease

Symptoms & Phenotypes for Optic Nerve Disease

UMLS symptoms related to Optic Nerve Disease:


eye manifestations, sciatica

MGI Mouse Phenotypes related to Optic Nerve Disease:

44
id Description MGI Source Accession Score Top Affiliating Genes
1 growth/size/body region MP:0005378 10 ANTXR1 AQP4 BTD DNM1L EDN1 MFN1
2 muscle MP:0005369 9.7 MFN2 MOG OPA1 OPA3 BTD DNM1L
3 nervous system MP:0003631 9.65 AQP4 DNM1L EDN1 MFN1 MFN2 MFRP
4 vision/eye MP:0005391 9.28 AQP4 BTD DNM1L MFRP MOG MT-ND6

Drugs & Therapeutics for Optic Nerve Disease

Drugs for Optic Nerve Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 838)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Dorzolamide Approved Phase 4,Phase 2,Phase 3 120279-96-1 3154 5284549
2
Timolol Approved Phase 4,Phase 3,Phase 2,Phase 1 26839-75-8 33624 5478
3
Bimatoprost Approved, Investigational Phase 4,Phase 3 155206-00-1 5311027
4
Latanoprost Approved, Investigational Phase 4,Phase 3 130209-82-4 5282380 5311221
5
Travoprost Approved Phase 4,Phase 3 157283-68-6 5282226
6
Methylprednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 83-43-2 6741
7
Prednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 50-24-8 5755
8
Prednisone Approved, Vet_approved Phase 4,Phase 3,Phase 2 53-03-2 5865
9
Mitoxantrone Approved, Investigational Phase 4 65271-80-9 4212
10
Acetazolamide Approved, Vet_approved Phase 4,Phase 2,Phase 3 59-66-5 1986
11
Glatiramer Acetate Approved, Investigational Phase 4,Phase 3,Phase 2 147245-92-9 3081884
12
Ranibizumab Approved Phase 4,Phase 3,Phase 2,Phase 1 347396-82-1 459903
13
Everolimus Approved Phase 4,Phase 3,Phase 2,Phase 1 159351-69-6 6442177
14
Sirolimus Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 53123-88-9 5284616 6436030 46835353
15
Gabapentin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 60142-96-3 3446
16
Ketorolac Approved Phase 4 74103-06-3, 66635-83-4 3826
17
Hyaluronic acid Approved, Vet_approved Phase 4 9004-61-9 53477741 24759
18
Pravastatin Approved Phase 4 81093-37-0 54687
19
Ticagrelor Approved Phase 4 274693-27-5 9871419
20
Ticlopidine Approved Phase 4 55142-85-3 5472
21
Isosorbide Dinitrate Approved Phase 4 87-33-2 6883
22
Nitric Oxide Approved Phase 4,Phase 2,Phase 1 10102-43-9 145068
23
Nicorandil Approved Phase 4 65141-46-0 47528
24
Mannitol Approved, Investigational Phase 4,Phase 3,Phase 2 69-65-8 453 6251
25
Methyltestosterone Approved Phase 4 58-18-4 6010
26
Testosterone Approved, Investigational Phase 4 58-22-0 6013
27
4-Aminopyridine Approved Phase 4,Phase 2,Phase 3 504-24-5 1727
28
Dopamine Approved Phase 4,Phase 3,Phase 2,Phase 1 51-61-6, 62-31-7 681
29
Bevacizumab Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 216974-75-3
30
Glycerol Approved, Experimental Phase 4,Phase 3 56-81-5 753
31
Loteprednol Approved Phase 4,Phase 1 82034-46-6, 129260-79-3 444025 9865442
32
Dexamethasone Approved, Investigational, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1 50-02-2 5743
33
Brinzolamide Approved Phase 4,Phase 3 138890-62-7 68844
34
Benzocaine Approved Phase 4,Phase 2 1994-09-7, 94-09-7 2337
35
Povidone-iodine Approved Phase 4,Phase 2 25655-41-8
36
Nepafenac Approved Phase 4 78281-72-8 151075
37
Midazolam Approved, Illicit Phase 4 59467-70-8 4192
38
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 22916-47-8 4189
39
Acetylcholine Approved Phase 4,Phase 3,Phase 1,Phase 2 51-84-3 187
40
Triamcinolone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 124-94-7 31307
41
Ephedrine Approved Phase 4,Phase 2,Phase 3,Phase 1 299-42-3 9294
42
Pseudoephedrine Approved Phase 4,Phase 2,Phase 3,Phase 1 90-82-4 7028
43
Morphine Approved, Investigational Phase 4 57-27-2 5288826
44
Exenatide Approved, Investigational Phase 4 141758-74-9 15991534
45
Zinc Approved Phase 4,Phase 3 7440-66-6 32051 23994
46
Carboplatin Approved Phase 4,Phase 3,Phase 2,Phase 1 41575-94-4 10339178 498142 38904
47
Etoposide Approved Phase 4,Phase 3,Phase 2,Phase 1 33419-42-0 36462
48
Vincristine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 2068-78-2, 57-22-7 5978
49
Doxycycline Approved, Investigational, Vet_approved Phase 4,Phase 2,Phase 3 564-25-0 54671203
50
Donepezil Approved Phase 4,Phase 2,Phase 1 120014-06-4 3152

Interventional clinical trials:

(show top 50) (show all 2017)
id Name Status NCT ID Phase
1 Impact of Timolol/Dorzolamide Therapy on Autoregulation in Glaucoma Patients Unknown status NCT02053298 Phase 4
2 Efficacy and Safety Study of Combigan and 0.5% Timoptic in Normal Tension Glaucoma Unknown status NCT01446497 Phase 4
3 The Secondary Beneficial Effects of Prostaglandin Analog Treatment in Thyroid Eye Disease Patients. Unknown status NCT01927406 Phase 4
4 A Phase IV Trial of Neuroprotection With ACTH in Acute Optic Neuritis Unknown status NCT01838174 Phase 4
5 Efficacy and Safety of Mitoxantrone in Patients With Refractory Neuromyelitis Optica and Spectrum Disorders Unknown status NCT02021825 Phase 4
6 ALPI vs Medical Therapy Effects on Optic Nerve Structure & Function Unknown status NCT00485238 Phase 4
7 Optical Coherence Tomography: Glatiramer in Clinically Isolated Syndrome or Early Relapsing Remitting Multiple Sclerosis (MS) Unknown status NCT00910598 Phase 4
8 Eyegaze Systems for Spinal Cord Injury: A Feasibility Study Unknown status NCT01943656 Phase 4
9 Evaluation of Changes in the Parameters of Optical Coherence Tomography After Intravitreal Injection of Lucentis Unknown status NCT01669447 Phase 4
10 Optical Coherence Tomography Comparison of Neointimal Coverage Between CRE8 DES and BMS Unknown status NCT01543373 Phase 4
11 Effect of Gabapentin on Pain of the Second Cataract Surgery Unknown status NCT02127853 Phase 4
12 Efficient Study of ACULAR in Inhibiting Proliferative Retinopathy in Prematurity Unknown status NCT00634972 Phase 4
13 A Safety Study of Hylan GF-20 to Treat Shoulder Osteoarthritis Unknown status NCT00253799 Phase 4
14 The Effects of Pravastatin and Rosuvastatin on Coronary Plaques in Patients With Stable Angina Pectoris Unknown status NCT01325818 Phase 4
15 Functional Electrical Stimulation (FES) Assisted Walking: Enhancement of Walking Function After Stroke Unknown status NCT00552916 Phase 4
16 Impact of Ticagrelor on the Endothelial Healing Following Drug-eluting Stent Implantation in the Patients With Acute Coronary Syndrome Unknown status NCT02037412 Phase 4
17 Influence of Nitrates on Bone Remodeling and Endothelial Function in Patients With Type 2 Diabetes Mellitus Unknown status NCT02011620 Phase 4
18 Efficacy Study of Nicorandil on Neointima Unknown status NCT02328521 Phase 4
19 Incidence of Acute Cerebrovascular Events Using Either Minimized or Standard Cardiopulmonary Bypass Circuit Unknown status NCT00862160 Phase 4
20 Bilateral Cochlear Implant Benefit in Young Children Unknown status NCT00424307 Phase 4
21 Safety and Efficacy of Anti-Pandemic H1N1 Vaccination in Rheumatic Diseases Unknown status NCT01151644 Phase 4
22 Intravitreal Ranibizumab for the Prevention of Radiation Maculopathy Following Plaque Radiotherapy Unknown status NCT00540930 Phase 4
23 Effects of Copaxone in the Retinal Function in Diabetic Patients After Panphotocoagulation Unknown status NCT00677664 Phase 4
24 Effect of Testosterone on Endothelial Function and Microcirculation in Type 2 Diabetic Patients With Hypogonadism Unknown status NCT01084369 Phase 4
25 Neural Conduction Along the Visual Pathways After Oral Treatment With Citicoline in Patients With Optic Nerve Diseases Completed NCT00404729 Phase 4
26 A New Medicine to Treat Nonarteritic Anterior Ischemic Optic Neuropathy (NAION) Completed NCT01975324 Phase 4
27 Effect of Levodopa-Carbidopa on Visual Function in Patients With Recent-Onset Nonarteritic Anterior Ischemic Optic Neuropathy Completed NCT00432393 Phase 4
28 Use of Bevacizumab in Trabeculectomy Surgery Completed NCT01166594 Phase 4
29 Brimonidine vs ALTP in Progressing Human Glaucoma Completed NCT00466479 Phase 4
30 Adjuvant Treatment of Graves´ Ophthalmopathy With NSAID (aGO Study) Completed NCT01458600 Phase 4
31 Observational Study of the Long-term Effect of Latanoprost in Normal Tension Glaucoma Completed NCT01209624 Phase 4
32 Investigation of Intraocular Pressure (IOP) Reduction Efficacy of Travoprost Ophthalmic Solution in Patients With Normal Tension Glaucoma Completed NCT01995136 Phase 4
33 A Pilot Study of Mitoxantrone for the Treatment of Recurrent Neuromyelitis Optica (Devic’s Disease) Completed NCT00304291 Phase 4
34 The DIOXXACT Trial(Diurnal IOP and OBF Xalatan vs Xalatan And Cosopt Trial) Completed NCT00957190 Phase 4
35 Pegaptanib for Retinal Edema Secondary to Diabetic Vascular Disease(Preserve) Study Completed NCT01486238 Phase 4
36 Long Term Study of Avonex Therapy Following a First Attack of Multiple Sclerosis Completed NCT00179478 Phase 4
37 Effect of High-Dose Prednisolone (Solu Dacortin®) Treatment on Choroidal and Optic Nerve Head Blood Flow in Humans Completed NCT00312325 Phase 4
38 Endocrine Dysfunction and Growth Hormone Deficiency in Children With Optic Nerve Hypoplasia Completed NCT00140413 Phase 4
39 Safety and Efficacy of Lansoprazole in Patients With Reflux Disease Completed NCT01135368 Phase 4
40 The Utility of in Vivo Confocal Microscopy to Assess Cellular Response and Efficacy of Long-term Topical Steroid Treatment in Patients With Dry Eye Disease Completed NCT02120079 Phase 4
41 Cystagon to Treat Infantile Neuronal Ceroid Lipofuscinosis Completed NCT00028262 Phase 4
42 Ocular-hypertensive Response to Topical Steroids in Children After Bilateral Strabismus Surgery Completed NCT02816905 Phase 4
43 A Study of the Structure and Function of the Retina in Adult Patients With Refractory Complex Partial Seizures Treated With Vigabatrin (Sabril®) Completed NCT01278173 Phase 4
44 Topical Brinzolamide Ophthalmic Suspension Versus Placebo in the Treatment of Infantile Nystagmus Syndrome Completed NCT01312402 Phase 4
45 Ophthalmic Findings During 10-year Enzyme Substitution of Danish Fabry Patients. Completed NCT01997489 Phase 4
46 Follow-up Study After 11 Years of Patients Who Were Included in the BENEFIT Trial (304747) With a First Demyelinating Event Suggestive of Multiple Sclerosis Completed NCT01795872 Phase 4
47 Study of Ocular Penetration of Topically Administered Fluoroquinolones Completed NCT00924729 Phase 4
48 Project Magnify - A Comparison of Two Strategies to Improve Reading Ability Completed NCT00366392 Phase 4
49 The Effect of Anaesthesia Depth on Oculo-cardiac Reflex Completed NCT02379546 Phase 4
50 Trial Comparing Daily Atropine Versus Weekend Atropine Completed NCT00094614 Phase 4

Search NIH Clinical Center for Optic Nerve Disease

Genetic Tests for Optic Nerve Disease

Genetic tests related to Optic Nerve Disease:

id Genetic test Affiliating Genes
1 Optic Neuropathy 29

Anatomical Context for Optic Nerve Disease

MalaCards organs/tissues related to Optic Nerve Disease:

39
Brain, Retina, Eye, Testes

The Foundational Model of Anatomy Ontology organs/tissues related to Optic Nerve Disease:

18
The Optic Nerve

Publications for Optic Nerve Disease

Articles related to Optic Nerve Disease:

(show top 50) (show all 59)
id Title Authors Year
1
Evaluation of Relative Afferent Pupillary Defect Using RAPDx Device in Patients with Optic Nerve Disease. ( 27928395 )
2016
2
Equating spatial summation in visual field testing reveals greater loss in optic nerve disease. ( 27197562 )
2016
3
Association between a relative afferent pupillary defect using pupillography and inner retinal atrophy in optic nerve disease. ( 26487800 )
2015
4
Comparison of acute non-visual bright light responses in patients with optic nerve disease, glaucoma and healthy controls. ( 26478261 )
2015
5
Optical coherence tomography shows retinal abnormalities associated with optic nerve disease. ( 24627251 )
2014
6
Optic nerve disease and axon pathophysiology. ( 23206593 )
2012
7
Electrical stimulation--a therapeutic strategy for retinal and optic nerve disease? ( 22282217 )
2012
8
Detection of optic nerve disease in retinoblastoma by use of spectral domain optical coherence tomography. ( 23084390 )
2012
9
[Animal models of human retinal and optic nerve diseases analysed using electroretinography]. ( 20387538 )
2010
10
Electrodiagnostic assessment in optic nerve disease. ( 19155758 )
2009
11
Ensemble adaptive network-based fuzzy inference system with weighted arithmetical mean and application to diagnosis of optic nerve disease from visual-evoked potential signals. ( 18468871 )
2008
12
The effect of generalized discriminate analysis (GDA) to the classification of optic nerve disease from VEP signals. ( 17709102 )
2008
13
Utilization of Discretization method on the diagnosis of optic nerve disease. ( 18571280 )
2008
14
Classification of macular and optic nerve disease by principal component analysis. ( 17046736 )
2007
15
Neural network-based diagnosing for optic nerve disease from visual-evoked potential. ( 17918693 )
2007
16
The role of the Met98Lys optineurin variant in inherited optic nerve diseases. ( 16885188 )
2006
17
Electrophysiological assessment of optic nerve disease. ( 15534599 )
2004
18
Gene therapy for optic nerve disease. ( 15534589 )
2004
19
Image analysis of optic nerve disease. ( 15534606 )
2004
20
Visual dysfunction in retinal and optic nerve disease. ( 12916487 )
2003
21
MRI to differentiate causes of optic nerve disease. ( 13129905 )
2003
22
Retinal masqueraders of optic nerve disease. ( 11370571 )
2001
23
Acquired mitochondrial impairment as a cause of optic nerve disease. ( 10360310 )
1998
24
Risk factors for optic nerve disease in communities mesoendemic for savannah onchocerciasis, Kaduna State, Nigeria. ( 9018306 )
1997
25
Optic nerve disease: an introduction. ( 9292246 )
1997
26
Spatial tuning loss of pattern reversal visual evoked response in optic nerve disease. ( 8739685 )
1996
27
Establishing a reliable visual function test and applying it to screening optic nerve disease in onchocercal communities. ( 8735773 )
1996
28
Red-dot card test of the paracentral field as a screening test for optic nerve disease in onchocerciasis. ( 9060216 )
1996
29
Nutrition and optic nerve disease. ( 10159744 )
1995
30
Flash visual evoked potential (VEP) in amblyopia and optic nerve disease. ( 8532302 )
1995
31
Reduction in incidence of optic nerve disease with annual ivermectin to control onchocerciasis. ( 8093742 )
1993
32
The pattern electroretinogram in retinal and optic nerve disease. A quantitative comparison of the pattern of visual dysfunction. ( 1760971 )
1991
33
Correlation of chromatic, spatial, and temporal sensitivity in optic nerve disease. ( 1748555 )
1991
34
The spectrum of optic nerve disease in human immunodeficiency virus infection. ( 2539020 )
1989
35
Pattern electroretinogram peak times as a clinical means of discriminating retinal from optic nerve disease. ( 2776633 )
1989
36
Standardized A-scan echography in optic nerve disease. ( 3307721 )
1987
37
The differential effect of optic nerve disease on pattern and focal electroretinograms. ( 3665701 )
1987
38
The pattern electroretinogram in patients with optic nerve disease. ( 3956359 )
1986
39
Stereoacuity in patients with optic nerve disease. ( 3977672 )
1985
40
Optic nerve disease. ( 3932417 )
1985
41
Brightness-sense and optic nerve disease. ( 3977673 )
1985
42
Improvement of uveitis and optic nerve disease by cyclosporine in a patient with multiple sclerosis. ( 6731549 )
1984
43
Edge-light pupil cycle time and optic nerve disease. ( 6660715 )
1983
44
The pattern electroretinogram in optic nerve disease. ( 6646652 )
1983
45
Vitreous fluorophotometry in optic nerve disease. ( 7104274 )
1982
46
Visual evoked potential and pupillary signs. A comparison in optic nerve disease. ( 7138329 )
1982
47
Auditory evoked phosphenes in optic nerve disease. ( 7062073 )
1982
48
Multiple regression analysis of diagnostic predictors in optic nerve disease. ( 7225960 )
1981
49
The differential diagnosis of retinal disease from optic nerve disease. ( 7328258 )
1981
50
Visual function tests in retinal and optic nerve disease. ( 487259 )
1979

Variations for Optic Nerve Disease

ClinVar genetic disease variations for Optic Nerve Disease:

6
id Gene Variation Type Significance SNP ID Assembly Location
1 MT-ND1 m.3700G> A single nucleotide variant Pathogenic rs397515508 GRCh37 Chromosome MT, 3700: 3700

Expression for Optic Nerve Disease

Search GEO for disease gene expression data for Optic Nerve Disease.

Pathways for Optic Nerve Disease

Pathways related to Optic Nerve Disease according to GeneCards Suite gene sharing:

id Super pathways Score Top Affiliating Genes
1 11.92 MFN1 MFN2 OPA1 WFS1
2
Show member pathways
11.54 MT-ND1 MT-ND4 MT-ND5 MT-ND6 NDUFA1
3 10.94 MFN1 MFN2 OPTN

GO Terms for Optic Nerve Disease

Cellular components related to Optic Nerve Disease according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 mitochondrial membrane GO:0031966 9.71 MT-ND1 MT-ND4 MT-ND6 NDUFA1
2 mitochondrial outer membrane GO:0005741 9.65 DNM1L MFN1 MFN2 MYOC OPA1
3 mitochondrial inner membrane GO:0005743 9.5 MT-ND1 MT-ND4 MT-ND5 MT-ND6 MYOC NDUFA1
4 mitochondrial respiratory chain complex I GO:0005747 9.46 MT-ND1 MT-ND4 MT-ND5 NDUFA1
5 intrinsic component of mitochondrial outer membrane GO:0031306 9.37 MFN1 MFN2
6 respiratory chain GO:0070469 9.02 MT-ND1 MT-ND4 MT-ND5 MT-ND6 NDUFA1
7 membrane GO:0016020 10.33 ANTXR1 AQP4 DNM1L MFN1 MFN2 MFRP
8 integral component of membrane GO:0016021 10.25 ANTXR1 AQP4 MFN1 MFN2 MFRP MOG
9 mitochondrion GO:0005739 10.02 DNM1L MFN1 MFN2 MT-ND1 MT-ND4 MT-ND5

Biological processes related to Optic Nerve Disease according to GeneCards Suite gene sharing:

(show all 16)
id Name GO ID Score Top Affiliating Genes
1 visual perception GO:0007601 9.78 MFRP OPA1 OPA3 WFS1
2 macroautophagy GO:0016236 9.69 MFN1 MFN2 OPTN
3 mitochondrial fission GO:0000266 9.56 DNM1L OPA1
4 positive regulation of cardiac muscle hypertrophy GO:0010613 9.55 EDN1 PDE5A
5 positive regulation of dendritic spine morphogenesis GO:0061003 9.54 DNM1L OPA1
6 negative regulation of endoplasmic reticulum stress-induced intrinsic apoptotic signaling pathway GO:1902236 9.52 OPA1 WFS1
7 response to nicotine GO:0035094 9.5 EDN1 MT-ND4 MT-ND6
8 dynamin family protein polymerization involved in mitochondrial fission GO:0003374 9.49 DNM1L OPA1
9 mitochondrion localization GO:0051646 9.46 MFN1 MFN2
10 intracellular distribution of mitochondria GO:0048312 9.43 DNM1L OPA1
11 mitochondrion morphogenesis GO:0070584 9.43 DNM1L OPA1 OPA3
12 ATP synthesis coupled electron transport GO:0042773 9.4 MT-ND4 MT-ND5
13 parkin-mediated mitophagy in response to mitochondrial depolarization GO:0061734 9.37 MFN2 OPTN
14 mitochondrial respiratory chain complex I assembly GO:0032981 9.35 MT-ND1 MT-ND4 MT-ND5 MT-ND6 NDUFA1
15 mitochondrial fusion GO:0008053 9.33 MFN1 MFN2 OPA1
16 mitochondrial electron transport, NADH to ubiquinone GO:0006120 9.02 MT-ND1 MT-ND4 MT-ND5 MT-ND6 NDUFA1

Molecular functions related to Optic Nerve Disease according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 GTPase activity GO:0003924 9.26 DNM1L MFN1 MFN2 OPA1
2 NADH dehydrogenase (ubiquinone) activity GO:0008137 9.02 MT-ND1 MT-ND4 MT-ND5 MT-ND6 NDUFA1

Sources for Optic Nerve Disease

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....